Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

2015175 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: Cancer Immunology Immunotherapy

Volume 64, Issue 8, pp. 999-1009

Field-Weighted Citation Impact: 6.02